Larada Therapeutics Inc

LAR-101

LAR-101 is a novel, first-in-class biologic ophthalmic solution, that provides rapid relief and long-lasting clinical benefits for patients with ocular surface diseases (Dry Eye Diseases - DEDs). Several of these diseases severely impact vision, have no ophthalmic standard of care (SoC), nor any approved therapies, including ocular Sjogren’s syndrome, ocular Rosacea, ocular Stevens-Johnson syndrome, and refractory DEDs. LAR-101 is a protein ophthalmic solution, first-in-class, potent, precision medicine and targeted therapeutics. It specifically selects and effectively eliminates ONLY disease-causing LFA1 expressing activated WBCs while sparing normal cells. Making it very selective, highly effective, fast-acting, long-lasting, safe and well-tolerated. LAR-101 has been tested in mouse, rat, dog and non-human primate. Even at once-a-week dosing, LAR-101 elicits rapid relief, long-lasting benefits, and improved quality of life. Coupled with its patient-friendly and convenient application, leading to increased compliance, reduced prescriptions, decreased doctor visits and related costs. LAR-101 is the next generation ophthalmic solution beyond Xiidra® / Restasis®, with potential to transform DED care in general. There is upsurge in, and constant use of digital screens, plus refractory, unserved, underserved with aging population and improved plus expanding diagnoses. All point to growing worldwide DED market. There is a vast worldwide demand for effective and long-lasting treatment for these DEDs especially in those with no SoC and no approved therapies. LAR-101 is evidently positioned to provide effective, efficient, convenient, safe and well-tolerated treatment with fast onset of relief and sustained clinical benefits.

Click to read more